MEN1 and acute leukemia: Other potentially promising agents are menin inhibitors, which have shown a significant reduction in leukemic cell load in mice engrafted with KMT2A-r AML.34 Additionally, in two recent phase 1 studies, treatment with the menin inhibitors SNDX-5613 (revumenib)35 and KO-539 (ziftomenib)36 appeared safe and showed encouraging clinical responses in patients with relapsed/refractory KMT2A-r acute leukemia and AML, respectively.